文献速递运动医学关节外科

富血小板血浆用于关节镜下肩袖修复:一项三臂随机对照试验

Platelet-Rich Plasma for Arthroscopic Rotator Cuff Repair: A 3-Arm Randomized Controlled Trial.
PubMed 文献 · Am J Sports Med · 2024-10-18

该随机对照试验将全层肩袖撕裂患者随机分为富白细胞富血小板血浆(LR-PRP)组、贫白细胞富血小板血浆(LP-PRP)组和标准护理对照组,比较关节镜下肩袖修复联合PRP注射的疗效。结果显示三组在12个月时UCLA评分无显著差异,但LR-PRP组在术后6个月内ASES评分优于对照组,总体再撕裂率和并发症发生率无显著差异。

要点

  • 三组12个月时UCLA评分无显著差异(P=0.169)。
  • LR-PRP组术后3个月和6个月ASES评分优于对照组。
  • 三组总体再撕裂率和完全再撕裂率无显著差异。

核心结论

  • 研究未显示LR-PRP或LP-PRP组在12个月时功能或结构结局优于对照组。
  • LR-PRP可能在术后6个月内提供更好的ASES评分,但其临床获益有待证实。

研究设计与样本

  • 随机对照试验,证据等级1级。
  • 纳入全层肩袖撕裂接受关节镜下修复的患者,随机分为LR-PRP组、LP-PRP组和标准护理对照组,主要分析按意向性治疗原则进行。
  • 初始随机150例,功能结局分析142例(LR-PRP组46例、LP-PRP组47例、对照组49例),结构完整性分析133例(LR-PRP组40例、LP-PRP组46例、对照组47例)。

主要发现

  • 三组主要结局UCLA评分无显著差异(P=0.169)。
  • 术后3个月ASES评分LR-PRP组85.8±4.1 vs 对照组81.6±8.7(P=0.011);术后6个月LR-PRP组90.0±5.4 vs 对照组86.2±6.8(P=0.003)。
  • 术后12个月总体再撕裂率(含部分和完全再撕裂)为8%,三组总体再撕裂率(P=0.755)和完全再撕裂率(P=0.633)无显著差异。
  • 唯一手术并发症为术后僵硬,发生率为3%,三组间发生率无显著差异(P=0.790)。

关键数值与推荐

  • 采用UCLA评分、Constant评分、ASES评分、睡眠和活动时疼痛视觉模拟评分及主动活动度评估功能结局,术后3、6、12个月随访,术后2周和6周获取视觉模拟评分。
  • 术后12个月采用磁共振成像Sugaya分类评估结构完整性,III型视为部分再撕裂,IV型和V型视为完全再撕裂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although there has been some amount of research into the use of platelet-rich plasma (PRP) after arthroscopic rotator cuff repair, most studies have not fully demonstrated its benefits. In addition, PRP formulations containing different concentrations of leukocytes have not been directly compared for rotator cuff repair. PURPOSE/HYPOTHESIS: The purpose of this article was to determine whether arthroscopic rotator cuff repair combined with PRP injection, either leukocyte-rich PRP (LR-PRP) or leukocyte-poor PRP (LP-PRP), is superior to the control. The null hypothesis was that the addition of any PRP formulation would not result in outcomes superior to the control group. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: Patients with full-thickness rotator cuff tears who underwent arthroscopic repair were assessed for eligibility. The included patients were randomized to 3 treatment groups: the LR-PRP, LP-PRP, and standard-care control groups. After the rotator cuff suture was fixed firmly, different groups of liquid PRP preparations prepared by centrifugation were injected into the tendon-to-bone interface. The functional outcomes were assessed using the University of California, Los Angeles (UCLA) score, the Constant score, the American Shoulder and Elbow Surgeons (ASES) score, the visual analog scale for pain during sleep and activity, and active range of motion at 3, 6, and 12 months after surgery. In addition, the visual analog scale score was obtained at weeks 2 and 6. Postoperative structural integrity was assessed by magnetic resonance imaging at 12 months using the Sugaya classification. Type III was considered partial retear, and types IV and V were considered complete retears. The safety of surgery was compared by the incidence of complications. The main analyses were performed in accordance with the intention-to-treat principle. RESULTS: Of 150 patients initially randomized, the functional outcomes in 142 (46 LR-PRP, 47 LP-PRP, 49 control) and the structural integrity in 133 (40 LR-PRP, 46 LP-PRP, 47 control) were analyzed. There was no significant difference in the primary outcome of the UCLA score among the 3 groups (P = .169). The trends in functional outcomes and range of motion were similar for the 3 groups, with no significant differences among the groups at 12 months. However, within 6 months after surgery, the ASES score was better in the LR-PRP group than in the control group (3 months: 85.8 ± 4.1 vs 81.6 ± 8.7; P = .011; 6 months: 90.0 ± 5.4 vs 86.2 ± 6.8; P = .003). At 12 months after surgery, the overall retear rate, including partial and complete retears, was 8%. There were no significant differences in the rates of overall retear (P = .755) or complete retear (P = .633) among the 3 groups. The only surgical complication was postoperative stiffness, which occurred in 3% of patients, and the incidence did not significantly differ among the groups (P = .790). CONCLUSION: The study did not reveal that shoulders treated with the LR-PRP or LP-PRP formulations had any superior functional or structural outcomes at 12 months compared with those of the control group. However, LR-PRP may offer better ASES scores than the control group up to 6 months after surgery, and its clinical benefit remains to be proven. REGISTRATION: ChiCTR2100045039 (Chinese Clinical Trial Register).

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Yao L, Pang L, Zhang C, et al. Platelet-Rich Plasma for Arthroscopic Rotator Cuff Repair: A 3-Arm Randomized Controlled Trial. Am J Sports Med. 2024. PMID: 39425250. doi:10.1177/03635465241283964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。